Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/μL who were assigned to 7.5 MIU interleukin-2

Zoe Fox; Francisco Antunes; Rick Davey; Brian Gazzard; Nancy Klimas; Ann Labriola; Marcelo Losso; James D. Neaton; Andrew Phillips; Kiat Ruxrungtham; Schlomo Staszewski; Laurence Weiss; D. Jens Lundgren; Liliana Aguilar; Eleonora Betina Angel; Silvia Aquilia; Waldo Belloso; Jorge Benetucci; Victor Bittar; Pedro Cahn; Arnaldo Casiro; Jorge Contarelli; Jorge Corral; Lucia Daciuk; Daniel David; Ines Ferrari; Diego Fridman; Viviana Galache; Graciela Guaragna; Silvina Ivalo; Hector Laplume; Isabel Lanusse; Maria B. Lasala; Roberta Lattes; Jaime Lasovsky; Gustavo Lopardo; Marcelo Losso; Leonardo Lourtau; Sergio Lupo; Aldo Maranzana; Cristina Marson; Lucila Massera; Marisa del Lujan Sanchez; Carla Somenzini; Mariel Tocci; Sally Algar; Jonathan Anderson; David Baker; Kathy Blavius; Mark Bloch; Michael Boyle; David Bradford; Phillip Britton; Leah Carrall; Andrew Carr; John Chuah; Michael Curry; Clive D'Arcy-Evans; Pauline Dobson; Nicholas Doong; Cari Egan; Wendy Ferguson; Robert Finlayson; Martyn French; Anthony Frater; Julian Gold; Philip Habel; Kay Haig; Rohan Holland; Natalie Hyland; Jennifer Hoy; Jeff Hudson; Robyn James; Jenny Leung; Kaye Lowe; Karen MacRae; Marilyn McMurchie; Nicholas Medland; Samantha Miller; Jo Murray; Rosie Newman; Orth David; Julie Patching; Ruth Primrose; Hugo Ree; Robyn Richardson; Gary Rogers; Janine Roney; Norman Roth; Jeganathan Sarangapany; David Shaw; Carol Silberberg; Alan Skett; Robyn Vale; Claudio Villella; Alan Walker; Ashley Watson; Ngaire Wendt; Helen Wood

doi:10.1111/j.1468-1293.2007.00440.x

Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/μL who were assigned to 7.5 MIU interleukin-2

Zoe Fox, Francisco Antunes, Rick Davey, Brian Gazzard, Nancy Klimas, Ann Labriola, Marcelo Losso, James D. Neaton, Andrew Phillips, Kiat Ruxrungtham, Schlomo Staszewski, Laurence Weiss, D. Jens Lundgren, Liliana Aguilar, Eleonora Betina Angel, Silvia Aquilia, Waldo Belloso, Jorge Benetucci, Victor Bittar, Pedro CahnArnaldo Casiro, Jorge Contarelli, Jorge Corral, Lucia Daciuk, Daniel David, Ines Ferrari, Diego Fridman, Viviana Galache, Graciela Guaragna, Silvina Ivalo, Hector Laplume, Isabel Lanusse, Maria B. Lasala, Roberta Lattes, Jaime Lasovsky, Gustavo Lopardo, Marcelo Losso, Leonardo Lourtau, Sergio Lupo, Aldo Maranzana, Cristina Marson, Lucila Massera, Marisa del Lujan Sanchez, Carla Somenzini, Mariel Tocci, Sally Algar, Jonathan Anderson, David Baker, Kathy Blavius, Mark Bloch, Michael Boyle, David Bradford, Phillip Britton, Leah Carrall, Andrew Carr, John Chuah, Michael Curry, Clive D'Arcy-Evans, Pauline Dobson, Nicholas Doong, Cari Egan, Wendy Ferguson, Robert Finlayson, Martyn French, Anthony Frater, Julian Gold, Philip Habel, Kay Haig, Rohan Holland, Natalie Hyland, Jennifer Hoy, Jeff Hudson, Robyn James, Jenny Leung, Kaye Lowe, Karen MacRae, Marilyn McMurchie, Nicholas Medland, Samantha Miller, Jo Murray, Rosie Newman, Orth David, Julie Patching, Ruth Primrose, Hugo Ree, Robyn Richardson, Gary Rogers, Janine Roney, Norman Roth, Jeganathan Sarangapany, David Shaw, Carol Silberberg, Alan Skett, Robyn Vale, Claudio Villella, Alan Walker, Ashley Watson, Ngaire Wendt, Helen Wood

Biostatistics

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Background: ESPRIT is a randomized trial comparing the clinical impact of interleukin (IL)-2 plus antiretrovirals vs antiretrovirals alone. Identification of factors that influence the relationship between IL-2 and CD4 count recovery will enable better personalization of treatment with IL-2 in HIV-1-positive individuals. The IL-2 induction phase consists of three dosing cycles over 6-8 months (7.5 MIU twice a day, for 5 days every 8 weeks). Methods: We included patients initiating IL-2 at the 7.5 MIU dose with an 8-month CD4 count, measured at least 30 days after their last cycle. We identified baseline predictors of CD4 count changes over 8 months using linear regression. Results: Of 2090 patients assigned IL-2, 1673 (80%) were included in the analysis. The median (interquartile range) baseline CD4 count was 461 (370, 587) cells/μL with a median increase of 233 (90, 411) cells/μL at month 8. After adjustments, significant predictors of CD4 count change included CD4 nadir (29.8 cells/μL greater increase per 100 cells/μL higher; P < 0.0001), last CD4 count before baseline (mean 36.0 cells/μL greater increase per 100 cells/μL higher; P < 0.0001), time from antiretroviral start to baseline (8.3 cells/μL smaller increase per year longer; P = 0.001), age (11.7 cells/μL smaller increase per 5 years older; P = 0.005) and race (79.7 cells/μL greater increase for black patients vs white patients; P = 0.003). A linear relationship existed between total IL-2 dose in the first cycle and CD4 count change (73.1 cells/μL greater increase per 15 MIU higher; P < 0.0001). Conclusions: Prior nadir and current CD4 counts, age and IL-2 dose are major determinants of CD4 increases induced by with intermittent administration of IL-2 in HIV-1-positive individuals on antiretrovirals. The clinical function of these induced CD4 cells is under study.

Original language	English (US)
Pages (from-to)	112-123
Number of pages	12
Journal	HIV Medicine
Volume	8
Issue number	2
DOIs	https://doi.org/10.1111/j.1468-1293.2007.00440.x
State	Published - Mar 2007

Keywords

7.5 MIU proleukin
CD4 cell count responses
Subcutaneous recombinant interleukin-2

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1111/j.1468-1293.2007.00440.x

OpenUrl availability

Full text

Cite this

Fox, Z., Antunes, F., Davey, R., Gazzard, B., Klimas, N., Labriola, A., Losso, M., Neaton, J. D., Phillips, A., Ruxrungtham, K., Staszewski, S., Weiss, L., Lundgren, D. J., Aguilar, L., Angel, E. B., Aquilia, S., Belloso, W., Benetucci, J., Bittar, V., ... Wood, H. (2007). Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/μL who were assigned to 7.5 MIU interleukin-2. HIV Medicine, 8(2), 112-123. https://doi.org/10.1111/j.1468-1293.2007.00440.x

Fox, Z, Antunes, F, Davey, R, Gazzard, B, Klimas, N, Labriola, A, Losso, M, Neaton, JD, Phillips, A, Ruxrungtham, K, Staszewski, S, Weiss, L, Lundgren, DJ, Aguilar, L, Angel, EB, Aquilia, S, Belloso, W, Benetucci, J, Bittar, V, Cahn, P, Casiro, A, Contarelli, J, Corral, J, Daciuk, L, David, D, Ferrari, I, Fridman, D, Galache, V, Guaragna, G, Ivalo, S, Laplume, H, Lanusse, I, Lasala, MB, Lattes, R, Lasovsky, J, Lopardo, G, Losso, M, Lourtau, L, Lupo, S, Maranzana, A, Marson, C, Massera, L, Sanchez, MDL, Somenzini, C, Tocci, M, Algar, S, Anderson, J, Baker, D, Blavius, K, Bloch, M, Boyle, M, Bradford, D, Britton, P, Carrall, L, Carr, A, Chuah, J, Curry, M, D'Arcy-Evans, C, Dobson, P, Doong, N, Egan, C, Ferguson, W, Finlayson, R, French, M, Frater, A, Gold, J, Habel, P, Haig, K, Holland, R, Hyland, N, Hoy, J, Hudson, J, James, R, Leung, J, Lowe, K, MacRae, K, McMurchie, M, Medland, N, Miller, S, Murray, J, Newman, R, David, O, Patching, J, Primrose, R, Ree, H, Richardson, R, Rogers, G, Roney, J, Roth, N, Sarangapany, J, Shaw, D, Silberberg, C, Skett, A, Vale, R, Villella, C, Walker, A, Watson, A, Wendt, N & Wood, H 2007, 'Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/μL who were assigned to 7.5 MIU interleukin-2', HIV Medicine, vol. 8, no. 2, pp. 112-123. https://doi.org/10.1111/j.1468-1293.2007.00440.x

@article{c6a182aa193745528774ddb766aaed9a,

title = "Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/μL who were assigned to 7.5 MIU interleukin-2",

abstract = "Background: ESPRIT is a randomized trial comparing the clinical impact of interleukin (IL)-2 plus antiretrovirals vs antiretrovirals alone. Identification of factors that influence the relationship between IL-2 and CD4 count recovery will enable better personalization of treatment with IL-2 in HIV-1-positive individuals. The IL-2 induction phase consists of three dosing cycles over 6-8 months (7.5 MIU twice a day, for 5 days every 8 weeks). Methods: We included patients initiating IL-2 at the 7.5 MIU dose with an 8-month CD4 count, measured at least 30 days after their last cycle. We identified baseline predictors of CD4 count changes over 8 months using linear regression. Results: Of 2090 patients assigned IL-2, 1673 (80%) were included in the analysis. The median (interquartile range) baseline CD4 count was 461 (370, 587) cells/μL with a median increase of 233 (90, 411) cells/μL at month 8. After adjustments, significant predictors of CD4 count change included CD4 nadir (29.8 cells/μL greater increase per 100 cells/μL higher; P < 0.0001), last CD4 count before baseline (mean 36.0 cells/μL greater increase per 100 cells/μL higher; P < 0.0001), time from antiretroviral start to baseline (8.3 cells/μL smaller increase per year longer; P = 0.001), age (11.7 cells/μL smaller increase per 5 years older; P = 0.005) and race (79.7 cells/μL greater increase for black patients vs white patients; P = 0.003). A linear relationship existed between total IL-2 dose in the first cycle and CD4 count change (73.1 cells/μL greater increase per 15 MIU higher; P < 0.0001). Conclusions: Prior nadir and current CD4 counts, age and IL-2 dose are major determinants of CD4 increases induced by with intermittent administration of IL-2 in HIV-1-positive individuals on antiretrovirals. The clinical function of these induced CD4 cells is under study.",

keywords = "7.5 MIU proleukin, CD4 cell count responses, Subcutaneous recombinant interleukin-2",

author = "Zoe Fox and Francisco Antunes and Rick Davey and Brian Gazzard and Nancy Klimas and Ann Labriola and Marcelo Losso and Neaton, {James D.} and Andrew Phillips and Kiat Ruxrungtham and Schlomo Staszewski and Laurence Weiss and Lundgren, {D. Jens} and Liliana Aguilar and Angel, {Eleonora Betina} and Silvia Aquilia and Waldo Belloso and Jorge Benetucci and Victor Bittar and Pedro Cahn and Arnaldo Casiro and Jorge Contarelli and Jorge Corral and Lucia Daciuk and Daniel David and Ines Ferrari and Diego Fridman and Viviana Galache and Graciela Guaragna and Silvina Ivalo and Hector Laplume and Isabel Lanusse and Lasala, {Maria B.} and Roberta Lattes and Jaime Lasovsky and Gustavo Lopardo and Marcelo Losso and Leonardo Lourtau and Sergio Lupo and Aldo Maranzana and Cristina Marson and Lucila Massera and Sanchez, {Marisa del Lujan} and Carla Somenzini and Mariel Tocci and Sally Algar and Jonathan Anderson and David Baker and Kathy Blavius and Mark Bloch and Michael Boyle and David Bradford and Phillip Britton and Leah Carrall and Andrew Carr and John Chuah and Michael Curry and Clive D'Arcy-Evans and Pauline Dobson and Nicholas Doong and Cari Egan and Wendy Ferguson and Robert Finlayson and Martyn French and Anthony Frater and Julian Gold and Philip Habel and Kay Haig and Rohan Holland and Natalie Hyland and Jennifer Hoy and Jeff Hudson and Robyn James and Jenny Leung and Kaye Lowe and Karen MacRae and Marilyn McMurchie and Nicholas Medland and Samantha Miller and Jo Murray and Rosie Newman and Orth David and Julie Patching and Ruth Primrose and Hugo Ree and Robyn Richardson and Gary Rogers and Janine Roney and Norman Roth and Jeganathan Sarangapany and David Shaw and Carol Silberberg and Alan Skett and Robyn Vale and Claudio Villella and Alan Walker and Ashley Watson and Ngaire Wendt and Helen Wood",

year = "2007",

month = mar,

doi = "10.1111/j.1468-1293.2007.00440.x",

language = "English (US)",

volume = "8",

pages = "112--123",

journal = "HIV Medicine",

issn = "1464-2662",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/μL who were assigned to 7.5 MIU interleukin-2

AU - Fox, Zoe

AU - Antunes, Francisco

AU - Davey, Rick

AU - Gazzard, Brian

AU - Klimas, Nancy

AU - Labriola, Ann

AU - Losso, Marcelo

AU - Neaton, James D.

AU - Phillips, Andrew

AU - Ruxrungtham, Kiat

AU - Staszewski, Schlomo

AU - Weiss, Laurence

AU - Lundgren, D. Jens

AU - Aguilar, Liliana

AU - Angel, Eleonora Betina

AU - Aquilia, Silvia

AU - Belloso, Waldo

AU - Benetucci, Jorge

AU - Bittar, Victor

AU - Cahn, Pedro

AU - Casiro, Arnaldo

AU - Contarelli, Jorge

AU - Corral, Jorge

AU - Daciuk, Lucia

AU - David, Daniel

AU - Ferrari, Ines

AU - Fridman, Diego

AU - Galache, Viviana

AU - Guaragna, Graciela

AU - Ivalo, Silvina

AU - Laplume, Hector

AU - Lanusse, Isabel

AU - Lasala, Maria B.

AU - Lattes, Roberta

AU - Lasovsky, Jaime

AU - Lopardo, Gustavo

AU - Losso, Marcelo

AU - Lourtau, Leonardo

AU - Lupo, Sergio

AU - Maranzana, Aldo

AU - Marson, Cristina

AU - Massera, Lucila

AU - Sanchez, Marisa del Lujan

AU - Somenzini, Carla

AU - Tocci, Mariel

AU - Algar, Sally

AU - Anderson, Jonathan

AU - Baker, David

AU - Blavius, Kathy

AU - Bloch, Mark

AU - Boyle, Michael

AU - Bradford, David

AU - Britton, Phillip

AU - Carrall, Leah

AU - Carr, Andrew

AU - Chuah, John

AU - Curry, Michael

AU - D'Arcy-Evans, Clive

AU - Dobson, Pauline

AU - Doong, Nicholas

AU - Egan, Cari

AU - Ferguson, Wendy

AU - Finlayson, Robert

AU - French, Martyn

AU - Frater, Anthony

AU - Gold, Julian

AU - Habel, Philip

AU - Haig, Kay

AU - Holland, Rohan

AU - Hyland, Natalie

AU - Hoy, Jennifer

AU - Hudson, Jeff

AU - James, Robyn

AU - Leung, Jenny

AU - Lowe, Kaye

AU - MacRae, Karen

AU - McMurchie, Marilyn

AU - Medland, Nicholas

AU - Miller, Samantha

AU - Murray, Jo

AU - Newman, Rosie

AU - David, Orth

AU - Patching, Julie

AU - Primrose, Ruth

AU - Ree, Hugo

AU - Richardson, Robyn

AU - Rogers, Gary

AU - Roney, Janine

AU - Roth, Norman

AU - Sarangapany, Jeganathan

AU - Shaw, David

AU - Silberberg, Carol

AU - Skett, Alan

AU - Vale, Robyn

AU - Villella, Claudio

AU - Walker, Alan

AU - Watson, Ashley

AU - Wendt, Ngaire

AU - Wood, Helen

PY - 2007/3

Y1 - 2007/3

N2 - Background: ESPRIT is a randomized trial comparing the clinical impact of interleukin (IL)-2 plus antiretrovirals vs antiretrovirals alone. Identification of factors that influence the relationship between IL-2 and CD4 count recovery will enable better personalization of treatment with IL-2 in HIV-1-positive individuals. The IL-2 induction phase consists of three dosing cycles over 6-8 months (7.5 MIU twice a day, for 5 days every 8 weeks). Methods: We included patients initiating IL-2 at the 7.5 MIU dose with an 8-month CD4 count, measured at least 30 days after their last cycle. We identified baseline predictors of CD4 count changes over 8 months using linear regression. Results: Of 2090 patients assigned IL-2, 1673 (80%) were included in the analysis. The median (interquartile range) baseline CD4 count was 461 (370, 587) cells/μL with a median increase of 233 (90, 411) cells/μL at month 8. After adjustments, significant predictors of CD4 count change included CD4 nadir (29.8 cells/μL greater increase per 100 cells/μL higher; P < 0.0001), last CD4 count before baseline (mean 36.0 cells/μL greater increase per 100 cells/μL higher; P < 0.0001), time from antiretroviral start to baseline (8.3 cells/μL smaller increase per year longer; P = 0.001), age (11.7 cells/μL smaller increase per 5 years older; P = 0.005) and race (79.7 cells/μL greater increase for black patients vs white patients; P = 0.003). A linear relationship existed between total IL-2 dose in the first cycle and CD4 count change (73.1 cells/μL greater increase per 15 MIU higher; P < 0.0001). Conclusions: Prior nadir and current CD4 counts, age and IL-2 dose are major determinants of CD4 increases induced by with intermittent administration of IL-2 in HIV-1-positive individuals on antiretrovirals. The clinical function of these induced CD4 cells is under study.

AB - Background: ESPRIT is a randomized trial comparing the clinical impact of interleukin (IL)-2 plus antiretrovirals vs antiretrovirals alone. Identification of factors that influence the relationship between IL-2 and CD4 count recovery will enable better personalization of treatment with IL-2 in HIV-1-positive individuals. The IL-2 induction phase consists of three dosing cycles over 6-8 months (7.5 MIU twice a day, for 5 days every 8 weeks). Methods: We included patients initiating IL-2 at the 7.5 MIU dose with an 8-month CD4 count, measured at least 30 days after their last cycle. We identified baseline predictors of CD4 count changes over 8 months using linear regression. Results: Of 2090 patients assigned IL-2, 1673 (80%) were included in the analysis. The median (interquartile range) baseline CD4 count was 461 (370, 587) cells/μL with a median increase of 233 (90, 411) cells/μL at month 8. After adjustments, significant predictors of CD4 count change included CD4 nadir (29.8 cells/μL greater increase per 100 cells/μL higher; P < 0.0001), last CD4 count before baseline (mean 36.0 cells/μL greater increase per 100 cells/μL higher; P < 0.0001), time from antiretroviral start to baseline (8.3 cells/μL smaller increase per year longer; P = 0.001), age (11.7 cells/μL smaller increase per 5 years older; P = 0.005) and race (79.7 cells/μL greater increase for black patients vs white patients; P = 0.003). A linear relationship existed between total IL-2 dose in the first cycle and CD4 count change (73.1 cells/μL greater increase per 15 MIU higher; P < 0.0001). Conclusions: Prior nadir and current CD4 counts, age and IL-2 dose are major determinants of CD4 increases induced by with intermittent administration of IL-2 in HIV-1-positive individuals on antiretrovirals. The clinical function of these induced CD4 cells is under study.

KW - 7.5 MIU proleukin

KW - CD4 cell count responses

KW - Subcutaneous recombinant interleukin-2

UR - http://www.scopus.com/inward/record.url?scp=33847773493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847773493&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1293.2007.00440.x

DO - 10.1111/j.1468-1293.2007.00440.x

M3 - Article

C2 - 17352768

AN - SCOPUS:33847773493

SN - 1464-2662

VL - 8

SP - 112

EP - 123

JO - HIV Medicine

JF - HIV Medicine

IS - 2

ER -

Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/μL who were assigned to 7.5 MIU interleukin-2

Abstract

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this